KLA Corporation
KLACKLA Corporation's price has outrun its earnings. +120.4% in a year against EPS +49.8% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +120.4% in a year while annual EPS moved +49.8% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (53 weeks in) while the P/E sits at the 95th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +10.1% year on year, and 108% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
KLA Corporation trades at $195, in a confirmed uptrend and 53 weeks into that stage. That is +19.6% against its own 200-day average. It sits at 63% of a 52-week range of $87 to $260. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 53 of stage 2. At $195 it trades +19.6% versus its 200-day average and sits at 63% of its 52-week range ($87–$260).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +2,548% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
KLA Corporation trades at 53.4× P/E, at the pricey end of its own range (95th percentile). Its long-run median P/E is 29.4×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 53.4× is at the pricey end of its own range (95th percentile), against a long-run median of 29.4× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +49.8% against a +120.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +57.9%/yr price move, ~+13.6%/yr came from earnings growth and ~+44.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
KLA Corporation reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +42.4% at its peak to +26.2% but is still expanding, ROCE lifting at 44.8%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +24.0% | +9.7% | — | — |
| Profit | +47.1% | +6.9% | — | — |
| EPS | +49.8% | +11.5% | — | — |
| Stock price | +120.4% | +57.9% | +40.8% | +38.1% |
4-Factor Sector Score
54.3/100 — rank 8 of 29 in Semiconductor Equipment & Materials · 58% evidence confidence
KLA Corporation scores 54.3 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 8. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.4 + 18.2 + 9.2 + 10.5 = 54.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
KLA Corporation reported $3.4 B of revenue in the Mar 26 quarter, +11.8% year on year. That is the 8th straight quarter of year-on-year growth. Over 4 years it has compounded at 15.1% a year. The last full year, FY25, came in at $12.2 B. The last four reported quarters add to $13.1 B.
FY25 revenue came in at $12.2 B (+24.0% on the year), capping 4 years at 15.1% compound. The latest quarter (Mar 26) printed $3.4 B, +11.8% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.8% growth against the decade's 15.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +13.4% over the last 4 quarters against +16.8%/yr over the last 8 — rolling over; TTM profit +26.2% vs +34.0%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
KLA Corporation's operating margin is 41.2% in the Mar 26 quarter, −1.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 34.1% to 39.6%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 41.2%, −1.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 34.1%–39.6%.
🚨 Why the margin moved: operating margin went −1.3 pp year on year while gross margin went −0.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
KLA Corporation earned $1.2 B of net profit in the Mar 26 quarter, +10.1% year on year. It is the 8th consecutive quarter of growth. Full-year FY25 profit was $4.1 B. The 4-year compound rate is 18.2%. That is 35.1% of the quarter's revenue. The same quarter a year earlier earned $1.1 B.
Mar 26 profit was $1.2 B, +10.1% year on year — the 8th consecutive quarter of growth. On the full year, FY25 printed $4.1 B (+47.1%), and the 4-year compound rate is 18.2%.
Why profit moved: revenue contributed +11.8% and the margin −1.3 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +27.8% vs revenue +13.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 108% of KLA Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $4.1 B of operating cash against $4.1 B of profit. After $0.3 B of capital spending, $3.8 B was left as free cash.
FY25: operating cash of $4.1 B against reported profit of $4.1 B, leaving free cash of $3.8 B after $0.3 B of capital spending. Across the last 3 fiscal years the conversion rate is 108% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
KLA Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 2.7% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
KLA Corporation earns a ROE of 87% in FY25. That is up from a trough of 62% in FY21. Return on invested capital clears the cost of that capital by +56.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 33.4% net margin on 0.76× asset turns.
FY25 ROE is 87%, recovered from a FY21 trough of 62% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 33.4% net margin × 0.76× asset turns × 3.43× balance-sheet leverage ≈ 87.1% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 68.0% − 11.8% = a +56.2 pp spread. The 11.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
KLA Corporation paid $0.76 per share over the last four reported quarters, up 11.8% on a year ago. The most recent declaration was $0.19 for Mar 26. Against the current price of $195 that is a trailing yield of 0.39%, measured on dividends already paid rather than on a forecast.
KLA Corporation paid $0.76 per share across the last four reported quarters, most recently $0.19 for Mar 26. That is up 11.8% against the same quarter a year earlier. Against the current price of $195 the trailing twelve months work out to 0.39% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
KLA Corporation carries total debt of $5.9 B against shareholder equity of $6.3 B as of Jun 26, a debt-to-equity of 0.93. On the annual view that ratio went from 1.02 in FY21 to 0.93 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $5.9 B against shareholder equity of $6.3 B — a debt-to-equity of 0.93. On the annual view, debt-to-equity went from 1.02 (FY21) to 0.93 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
2.1% of KLA Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 1.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 2.1% of the float is sold short, and at typical trading volumes it would take about 1.8 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
KLA Corporation: the Z-score reads 12.01. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 12.01 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 12.01.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Teradyne, Inc.TER | 69.6/100Thin evidence · provisional58% evidence | TURNING | 24.3/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 18.4/25 ROCE 12.7% · OPM 36.9% 76% evidence | 10.1/20 P/E 59.9× · PEG — 15% evidence | 16.8/20 RS sector 5.5% · RS bench 40% · 1Y 275.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 18.4 + 10.1 + 16.8 = 69.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Applied Materials, Inc.AMAT | 68.2/100Favorable setup85% evidence | LEADER | 22.1/35 Revenue 3.3% · PAT 25.9% · OPM change 1.4 pp 95% evidence | 16.4/25 ROCE 8.9% · OPM 31.9% 76% evidence | 11.1/20 P/E 39.2× · PEG 1.32 65% evidence | 18.6/20 RS sector 7.8% · RS bench 44.6% · 1Y 195.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 16.4 + 11.1 + 18.6 = 68.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Lam Research CorporationLRCX | 63.8/100Thin evidence · provisional58% evidence | FADING | 21.9/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence | 19.4/25 ROCE 15.5% · OPM 35% 76% evidence | 9.6/20 P/E 65.8× · PEG — 15% evidence | 12.9/20 RS sector -2.8% · RS bench 30.9% · 1Y 212.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 19.4 + 9.6 + 12.9 = 63.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4ACM Research, Inc.ACMR | 60.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 17.6/35 Revenue 19.7% · PAT -9% · OPM change 0.6 pp 83% evidence | 11.8/25 ROCE 2% · OPM 15.6% 76% evidence | 14.7/20 P/E 30× · PEG 0.75 65% evidence | 16.8/20 RS sector 2.7% · RS bench 38.8% · 1Y 244.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.8 + 14.7 + 16.8 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5ASML Holding N.V.ASML | 56.1/100Mixed-positive evidence85% evidence | FADING | 22.6/35 Revenue 9.8% · PAT 13.5% · OPM change 2.5 pp 95% evidence | 17.5/25 ROCE 11% · OPM 37.1% 76% evidence | 4.7/20 P/E 63.3× · PEG 4.28 65% evidence | 11.3/20 RS sector -15.3% · RS bench 18.8% · 1Y 137%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 17.5 + 4.7 + 11.3 = 56.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 6Kulicke and Soffa Industries, Inc.KLIC | 55.0/100Thin evidence · provisional58% evidence | FADING | 23.2/35 Revenue — · PAT — · OPM change 20 pp 45% evidence | 12.6/25 ROCE 4% · OPM 15.9% 76% evidence | 9.8/20 P/E 61.6× · PEG — 15% evidence | 9.4/20 RS sector -4.9% · RS bench 26.7% · 1Y 165%10 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 12.6 + 9.8 + 9.4 = 55 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7FormFactor, Inc.FORM | 54.6/100Thin evidence · provisional58% evidence | ASLEEP | 22.5/35 Revenue — · PAT — · OPM change 5.5 pp 45% evidence | 12.7/25 ROCE 5.2% · OPM 7.4% 76% evidence | 9.0/20 P/E 89.5× · PEG — 15% evidence | 10.4/20 RS sector 1.3% · RS bench 30.9% · 1Y 320.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 12.7 + 9 + 10.4 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8KLA Corporationthis pageKLAC | 54.3/100Thin evidence · provisional58% evidence | FADING | 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 45% evidence | 18.2/25 ROCE 12.1% · OPM 41.2% 76% evidence | 9.2/20 P/E 82.4× · PEG — 15% evidence | 10.5/20 RS sector -15.5% · RS bench 16.9% · 1Y 113.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 18.2 + 9.2 + 10.5 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Cohu, Inc.COHU | 52.8/100Thin evidence · provisional58% evidence | FADING | 20.1/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 5.4/25 ROCE 0% · OPM -8.9% 76% evidence | 9.9/20 P/E 60× · PEG — 15% evidence | 17.4/20 RS sector 5.2% · RS bench 41.2% · 1Y 172.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 5.4 + 9.9 + 17.4 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10AXT, Inc.AXTI | 51.3/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 47.2 pp 45% evidence | 7.0/25 ROCE 1.7% · OPM -5.9% 76% evidence | 8.5/20 P/E 3604× · PEG — 15% evidence | 13.7/20 RS sector 36.7% · RS bench 50.9% · 1Y 2950%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 7 + 8.5 + 13.7 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Aehr Test Systems, Inc.AEHR | 48.8/100Thin evidence · provisional58% evidence | TURNING | 15.7/35 Revenue — · PAT — · OPM change -34.9 pp 45% evidence | 5.0/25 ROCE -0.7% · OPM -41% 76% evidence | 11.5/20 P/E 12.4× · PEG — 15% evidence | 16.6/20 RS sector 65.3% · RS bench 106.2% · 1Y 503.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 5 + 11.5 + 16.6 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Amkor Technology, Inc.AMKR | 48.3/100Thin evidence · provisional58% evidence | FADING | 21.0/35 Revenue — · PAT — · OPM change 3.6 pp 45% evidence | 12.5/25 ROCE 3% · OPM 6% 76% evidence | 10.8/20 P/E 38.7× · PEG — 15% evidence | 4.0/20 RS sector -23% · RS bench 4.2% · 1Y 141.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 12.5 + 10.8 + 4 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Amtech Systems, Inc.ASYS | 48.2/100Thin evidence · provisional58% evidence | FADING | 20.5/35 Revenue -13.2% · PAT — · OPM change 211.5 pp 62% evidence | 9.3/25 ROCE 2.5% · OPM 8.8% 76% evidence | 9.3/20 P/E 68.7× · PEG — 15% evidence | 9.1/20 RS sector -11.2% · RS bench 19.9% · 1Y 259.6%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.5 + 9.3 + 9.3 + 9.1 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Ichor Holdings, Ltd.ICHR | 47.0/100Mixed-negative evidence64% evidence | FADING | 16.6/35 Revenue 7.6% · PAT — · OPM change 1.3 pp 62% evidence | 5.8/25 ROCE 0.2% · OPM 0.8% 76% evidence | 10.4/20 P/E 48.1× · PEG — 15% evidence | 14.2/20 RS sector 20.6% · RS bench 48.4% · 1Y 308.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 5.8 + 10.4 + 14.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 48.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Nova Ltd.NVMI | 46.4/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 21.4% · PAT 24.6% · OPM change 0.5 pp 83% evidence | 15.7/25 ROCE 5.6% · OPM 30.1% 76% evidence | 6.7/20 P/E 54.1× · PEG 2.56 65% evidence | 2.6/20 RS sector -34.6% · RS bench -7.4% · 1Y 53%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 15.7 + 6.7 + 2.6 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Photronics, Inc.PLAB | 45.4/100Mixed-negative evidence85% evidence | ASLEEP | 14.4/35 Revenue 0.5% · PAT 24.1% · OPM change -6.3 pp 95% evidence | 13.8/25 ROCE 2.6% · OPM 20.1% 76% evidence | 16.3/20 P/E 18.2× · PEG 0.43 65% evidence | 0.9/20 RS sector -36.1% · RS bench -9.2% · 1Y 61.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 13.8 + 16.3 + 0.9 = 45.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17Ultra Clean Holdings, Inc.UCTT | 44.3/100Mixed-negative evidence64% evidence | FADING | 12.9/35 Revenue -3.2% · PAT -574.4% · OPM change -0.4 pp 62% evidence | 6.6/25 ROCE 0.7% · OPM 2.1% 76% evidence | 10.9/20 P/E 35.5× · PEG — 15% evidence | 13.9/20 RS sector 11.3% · RS bench 40.5% · 1Y 264.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 6.6 + 10.9 + 13.9 = 44.3 · Decision use: Price leads the evidence: RS versus the benchmark is 40.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Onto Innovation Inc.ONTO | 44.3/100Thin evidence · provisional56% evidence | FADING | 12.9/35 Revenue — · PAT — · OPM change -18.5 pp 39% evidence | 9.9/25 ROCE 0.7% · OPM 5.2% 76% evidence | 10.2/20 P/E 59.7× · PEG — 15% evidence | 11.3/20 RS sector -5.6% · RS bench 27.8% · 1Y 179.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 9.9 + 10.2 + 11.3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Ambarella, Inc.AMBA | 44.2/100Mixed-negative evidence64% evidence | FADING | 22.3/35 Revenue 27.8% · PAT — · OPM change 10.8 pp 71% evidence | 3.5/25 ROCE -3.2% · OPM -19.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.4/20 RS sector -34.4% · RS bench 2.6% · 1Y 27.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 3.5 + 10 + 8.4 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20InTest CorporationINTT | 44.0/100Thin evidence · provisional58% evidence | ASLEEP | 19.5/35 Revenue -5.5% · PAT — · OPM change 13.6 pp 62% evidence | 8.2/25 ROCE 0.8% · OPM 2.8% 76% evidence | 8.6/20 P/E 341.3× · PEG — 15% evidence | 7.7/20 RS sector -16.9% · RS bench 13.1% · 1Y 103.8%4 of 12 weeks ahead 70% evidence |
| Exact sum: 19.5 + 8.2 + 8.6 + 7.7 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Entegris, Inc.ENTG | 42.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue -0.3% · PAT -14.8% · OPM change 1.6 pp 83% evidence | 10.9/25 ROCE 1.8% · OPM 17.4% 76% evidence | 7.7/20 P/E 67× · PEG 1.93 65% evidence | 9.5/20 RS sector -19% · RS bench 14.7% · 1Y 97.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 10.9 + 7.7 + 9.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Camtek Ltd.CAMT | 39.3/100Mixed-negative evidence81% evidence | ASLEEP | 11.0/35 Revenue 10.6% · PAT -61.7% · OPM change -5.2 pp 83% evidence | 13.5/25 ROCE 2.7% · OPM 22.4% 76% evidence | 11.8/20 P/E 174.3× · PEG 0.8 65% evidence | 3.0/20 RS sector -29.6% · RS bench -0.7% · 1Y 82.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 13.5 + 11.8 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23IPG Photonics CorporationIPGP | 39.2/100Mixed-negative evidence74% evidence | ASLEEP | 14.8/35 Revenue 9.2% · PAT — · OPM change -3.7 pp 62% evidence | 6.8/25 ROCE -0.4% · OPM -2.9% 76% evidence | 13.0/20 P/E 166.1× · PEG 0.67 65% evidence | 4.6/20 RS sector -40.8% · RS bench -14% · 1Y 25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 6.8 + 13 + 4.6 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Axcelis Technologies, Inc.ACLS | 38.6/100Mixed-negative evidence81% evidence | FADING | 7.8/35 Revenue -11.8% · PAT -44.1% · OPM change -11.1 pp 83% evidence | 9.8/25 ROCE 0.7% · OPM 4% 76% evidence | 12.5/20 P/E 29× · PEG 1.16 65% evidence | 8.5/20 RS sector -16% · RS bench 18.4% · 1Y 75.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 7.8 + 9.8 + 12.5 + 8.5 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Veeco Instruments Inc.VECO | 37.1/100Mixed-negative evidence81% evidence | FADING | 6.8/35 Revenue -7.8% · PAT -64.1% · OPM change -10.2 pp 83% evidence | 7.2/25 ROCE -0.2% · OPM -1.7% 76% evidence | 13.7/20 P/E 89.1× · PEG 0.65 65% evidence | 9.4/20 RS sector -8.9% · RS bench 25% · 1Y 128%9 of 12 weeks ahead 100% evidence |
| Exact sum: 6.8 + 7.2 + 13.7 + 9.4 = 37.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26Daqo New Energy Corp.DQ | 28.0/100Thin evidence · provisional58% evidence | BASING | 9.2/35 Revenue -22.8% · PAT — · OPM change -472.4 pp 62% evidence | 4.4/25 ROCE -2.6% · OPM -564.4% 76% evidence | 11.4/20 P/E 12.5× · PEG — 15% evidence | 3.0/20 RS sector -68.5% · RS bench -48.5% · 1Y -36.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 4.4 + 11.4 + 3 = 28 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Trio-Tech InternationalTRT | 53.0/100Thin evidence · provisional14% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 12.5/25 ROCE — · OPM — 0% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.0/20 RS sector 0.1% · RS bench 43.9% · 1Y 259.6%8 of 8 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 17.5 + 12.5 + 10 + 13 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Qnity Electronics, Inc.Q | 52.2/100Thin evidence · provisional38% evidence | ASLEEP | 16.7/35 Revenue — · PAT — · OPM change -0.4 pp 45% evidence | 15.0/25 ROCE 4.2% · OPM 20.6% 76% evidence | 10.5/20 P/E 45.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 16.7 + 15 + 10.5 + 10 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Atomera IncorporatedATOM | 43.8/100Thin evidence · provisional43% evidence | FADING | 21.8/35 Revenue — · PAT — · OPM change 79084.1 pp 39% evidence | 4.9/25 ROCE -19.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.1/20 RS sector -20% · RS bench 6.9% · 1Y 60.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 21.8 + 4.9 + 10 + 7.1 = 43.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is KLA Corporation's stock price today?
KLA Corporation trades at $195, +120.4% over the past year. The company is valued at $255 B. The stock sits at 63% of its 52-week range of $87–$260, +19.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 53 weeks in. — as of 5 August 2026.
What were KLA Corporation's latest quarterly results?
KLA Corporation reported revenue of $3.4 B and net profit of $1.2 B for the Mar 26 quarter. Revenue rose 11.8% and profit rose 10.1% year on year. Earnings per share were $0.91. The operating margin was 41.2%, 1.3 pp lower than a year earlier. — as of 5 August 2026.
What is KLA Corporation's revenue?
KLA Corporation reported revenue of $3.4 B in the Mar 26 quarter, +11.8% year on year. For the full FY25 fiscal year, revenue was $12.2 B (+24.0%). Over the last 4 years revenue compounded at 15.1% a year. — as of 5 August 2026.
What is KLA Corporation's profit?
KLA Corporation earned $1.2 B of net profit in the Mar 26 quarter, +10.1% year on year — the 8th straight quarter of growth. Full-year FY25 profit was $4.1 B. The operating margin ran 41.2% in the latest quarter. — as of 5 August 2026.
What is KLA Corporation's market cap?
KLA Corporation's market capitalisation is $255 B at a stock price of $195. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is KLA Corporation's P/E ratio?
KLA Corporation trades at a P/E of 53.4×, at the 95th percentile of its own 4-year range, against a long-run median of 29.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does KLA Corporation pay a dividend?
Yes — KLA Corporation declared $0.19 per share for Mar 26, and $0.76 per share across the last four reported quarters. The latest quarter is up 11.8% on the same quarter a year earlier. — as of 5 August 2026.
What is KLA Corporation's dividend per share?
KLA Corporation's most recently declared dividend is $0.19 per share for Mar 26, giving $0.76 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is KLA Corporation's dividend yield?
KLA Corporation's trailing dividend yield is 0.39%: $0.76 declared per share across the last four reported quarters, against a share price of $195. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is KLA Corporation overvalued?
On its own history, KLA Corporation looks expensive against its own history: its P/E of 53.4× sits at the 95th percentile of its 4-year range (long-run median 29.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is KLA Corporation growing?
Yes — KLA Corporation is growing: latest-quarter revenue +11.8% year on year, profit +10.1%, and the margin −1.3 pp at 41.2%. The 4-year compound rates are 15.1% (revenue) and 18.2% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is KLA Corporation performing?
KLA Corporation is in a confirmed uptrend, 53 weeks in. Its latest quarter's revenue rose 11.8% and profit rose 10.1% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is KLA Corporation in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +42.4% at its peak to +26.2% but is still expanding, ROCE lifting at 44.8%. The read comes from the last 12 quarters of growth (revenue growth +13.4% latest, profit growth +26.2% latest, eps growth +28.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is KLA Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 53 of stage 2), trading +19.6% versus its 200-day average and at 63% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is KLA Corporation beating the market?
Not lately — on a trailing-13-week view KLA Corporation is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +2,548% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will KLA Corporation's stock price go up?
This page publishes no price forecast for KLA Corporation. What it measures instead: the stock price is $195, the price is in a confirmed uptrend 53 weeks in. Its P/E of 53.4× sits at the 95th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against KLA Corporation?
Somewhat — short interest is 2.1% of KLA Corporation's tradable float, about 1.8 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does KLA Corporation have too much debt?
It is moderate — KLA Corporation's debt-to-equity is 0.93. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is KLA Corporation's capex?
KLA Corporation spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.3 B. — as of 5 August 2026.
What is KLA Corporation's cash flow?
KLA Corporation generated $4.1 B of operating cash flow in FY25 and $3.8 B of free cash flow after $0.3 B of capital spending. Reported profit that year was $4.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is KLA Corporation's profit real cash?
Yes — over the last 3 fiscal years, 108% of KLA Corporation's reported profit arrived as operating cash. In FY25, operating cash was $4.1 B against reported profit of $4.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is KLA Corporation?
On the balance sheet, the Z-score reads 12.01 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is KLA Corporation in its business cycle?
KLA Corporation's FY25 operating margin was 39.3%, against a 5-year band of 34.1%–39.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 41.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the KLA Corporation story?
The sharpest disagreement: the price moved +120.4% in a year while annual EPS moved +49.8% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is KLA Corporation a stock worth studying right now?
This is not investment advice. The machine read: KLA Corporation's price has outrun its earnings. +120.4% in a year against EPS +49.8% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.